Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail)

v3.22.1
Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Revenue Recognition [Line Items]    
Total research and development revenue $ 8,486 $ 3,220
Millennium Pharmaceuticals Inc    
Revenue Recognition [Line Items]    
Total research and development revenue 2,586 237
Millennium Pharmaceuticals Inc | Takeda Development and License Agreement    
Revenue Recognition [Line Items]    
Total research and development revenue 0 215
Millennium Pharmaceuticals Inc | Takeda Multi-Target Agreement    
Revenue Recognition [Line Items]    
Total research and development revenue $ 2,586 $ 22